Clotting disorders

Rivaroxaban cardioprotection outweighs bleeding risk: COMPASS re-analysis

The cardioprotective effect of rivaroxaban combined with low dose aspirin greatly outweighs the bleeding risk, especially in high-risk patients, a new analysis of the landmark COMPASS study shows. In 2017 the rivaroxaban trial in people with stable cardiovascular disease was stopped early because of “overwhelming efficacy” in reducing the risk of MI, stroke and cardiovascular ...

Already a member?

Login to keep reading.

© 2020 the limbic